Press Releases

Press releases ordered by year

Subscribe to our Press releases RSS Feed

• 2012

  • January 25

    Prosensa rondt succesvol € 23 miljoen financiering af, geleid door het Amerikaanse New Enterprise Associates

  • January 25

    Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates

• 2011

  • December 1

    Prosensa to Receive $1.5m from Charley’s Fund for Skipping of Exon 52 in Duchenne Muscular Dystrophy Patients

  • November 17

    Prosensa Updates on Patent Position

  • November 8

    Prosensa named Most Innovative European Biotech SME

  • November 8

    Prosensa uitgeroepen tot Meest Innovatieve Biotech MKB-onderneming van Europa

  • October 25

    Prosensa ontvangt tot €5 miljoen Innovatiekrediet van AgentschapNL voor onderzoek naar myotone dystrofie

  • October 25

    Prosensa Awarded up to €5m Innovation Credit from Dutch Government for research in Myotonic Dystrophy

  • September 13

    Prosensa brengt drie kandidaat medicijnen voor exon skipping tegen de ziekte van Duchenne in volgende ontwikkelingsfase - Prosensa kan tot in totaal EUR 31 miljoen aan ontwikkelingsbijdragen en mijlpaalbetalingen ontvangen van GSK

  • September 12

    Prosensa Advances Three Exon Skipping Candidates for Duchenne Muscular Dystrophy into the Next Development Stage - Prosensa to receive up to £27M in development and milestone payments from GSK

  • March 24

    Results of Prosensa’s Extended Phase I/II Exon-skipping Trial in Duchenne Muscular Dystrophy Published in the New England Journal of Medicine

  • February 28

    Life sciences bedrijf Prosensa groeit uit z’n jasje (distributed in The Netherlands, Dutch language)

  • January 19

    GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication

• 2010

  • October 13

    Prosensa receives £7.5m milestone payment as part of its program with GlaxoSmithKline in Duchenne Muscular Dystrophy

  • June 23

    Prosensa and GlaxoSmithKline initiate development of four additional products under existing alliance in Duchenne Muscular Dystrophy - Broadened program marks key inflexion in Prosensa’s progress to a fully integrated specialty-pharma

  • March 30

    Prosensa initiates clinical development of PRO044 in an open label phase I/II study - Prosensa’s second clinical candidate for treatment of Duchenne Muscular Dystrophy

  • March 17

    Prosensa strengthens its management team - Berndt Modig appointed as Chief Financial Officer

• 2009

  • October 13

    Prosensa and GlaxoSmithKline form alliance to fight Duchenne Muscular Dystrophy

  • September 30

    Prosensa, the Dutch based biopharmaceutical company focusing on RNA therapeutics and Leiden University Medical Center announce that they have extended their license agreement on RNA modulation.

  • September 14

    Prosensa’s RNA based therapeutic PRO051 shows favourable results in the first systemic study in patients with Duchenne muscular dystrophy

  • September 8

    Prosensa to Present Data at the World Muscle Society Congress

  • August 31

    Prosensa and TREAT-NMD enter into strategic collaboration for PRO-051 clinical trial planning

  • August 17

    Prosensa receives notice of allowance for key patent related to lead compound in development for Duchenne Muscular Dystrophy

• 2008

  • December 17

    Prosensa raises EUR 18 million Series B financing

  • May 6

    Prosensa strengthens board with two new board members

  • May 5

    Prosensa announces the start of an international multi-center phase I/II clinical study with ‘smart drug’ PRO051 in patients with Duchenne Muscular Dystrophy

• 2007

  • February 9

    Prosensa strengthens key team by appointing Head of Research

  • January 5

    Prosensa raises $18 million Series A financing led by LSP and Abingworth

• 2006

  • October 10

    Prosensa and Professor Qi Lu to collaborate on ‘smart therapy’ for Duchenne Muscular Dystrophy

  • May 10

    Prosensa and LUMC get approval for in-human trial for ‘smart therapy’ to cure Duchenne Muscular Dystrophy

  • January 26

    Prosensa receives more than € 3.2 million to develop a curative treatment for Duchenne Muscular Dystrophy

  • January 24

    EMEA grants PROSENSA orphan drug designation for the treatment of Duchenne Muscular Dystrophy using Exon skipping

• 2005

  • December 6

    FDA grants PROSENSA orphan drug designation for the treatment of Duchenne muscular dystrophy using Exon skipping

  • April 27

    Senter grants IS subsidy to Prosensa for the collaboration with the Radboud University Nijmegen Medical Centre (RUN-MC) on Myotonic Dystrophy

• 2004

  • December 20

    Senter grants IS subsidy to Prosensa for the collaboration with the LUMC on Duchenne Muscular Dystrophy

  • December 18

    CureDuchenne to fund Prosensa for the pre-clinical and clinical development of a potential Duchenne Muscular Dystrophy therapy

  • December 14

    Duchenne Parent Project NL and United Parent Projects Muscular Dystrophy (UPPMD) grant subsidy to Prosensa for the collaboration with the LUMC on Duchenne Muscular Dystrophy

  • December 14

    Prosensa appoints two board members

  • August 5

    Professor Jacques van Boom (67) deceased

  • March 18

    Senter grants second TS subsidy to Prosensa for the collaboration with the LUMC on Duchenne Muscular Dystrophy